End‐stage renal disease · adults and children who have IgA nephropathy proven on renal biopsy
It is very uncertain whether MMF regimen changes end‐stage kidney disease compared with no MMF regimen (very low certainty).
1 finding from 1 review
Complete remission · adults and children who have IgA nephropathy proven on renal biopsy
It is very uncertain whether MMF regimen changes complete remission compared with no MMF regimen (very low certainty).
1 finding from 1 review
GFR loss ≥ 50% · adults and children who have IgA nephropathy proven on renal biopsy
It is very uncertain whether MMF regimen changes GFR loss ≥ 50% compared with no MMF regimen (very low certainty).
1 finding from 1 review
Annual GFR loss (mL/min/1.73 m2) · adults and children who have IgA nephropathy proven on renal biopsy
1 finding from 1 review
Death (any cause) · adults and children who have IgA nephropathy proven on renal biopsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete remission · adults and children who have IgA nephropathy proven on renal biopsy
Systemic corticosteroid may leads to higher complete remission compared with no corticosteroid regimen (low certainty).
1 finding from 1 review
Infection · adults and children who have IgA nephropathy proven on renal biopsy
It is very uncertain whether MMF regimen changes infection compared with no MMF regimen (very low certainty).
1 finding from 1 review
Malignancy · adults and children who have IgA nephropathy proven on renal biopsy
It is very uncertain whether MMF regimen changes malignancy compared with no MMF regimen (very low certainty).
1 finding from 1 review
End‐stage renal disease · adults and children who have IgA nephropathy proven on renal biopsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete remission · adults and children who have IgA nephropathy proven on renal biopsy
It is very uncertain whether calcineurin inhibitor regimen changes complete remission compared with no calcineurin inhibitor regimen (very low certainty).
1 finding from 1 review
GFR loss ≥ 50% · adults and children who have IgA nephropathy proven on renal biopsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Annual GFR loss (mL/min/1.73 m2) · adults and children who have IgA nephropathy proven on renal biopsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death (any cause) · adults and children who have IgA nephropathy proven on renal biopsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Infection · adults and children who have IgA nephropathy proven on renal biopsy
It is very uncertain whether calcineurin inhibitor regimen changes infection compared with no calcineurin inhibitor regimen (very low certainty).
1 finding from 1 review
Malignancy · adults and children who have IgA nephropathy proven on renal biopsy
It is very uncertain whether calcineurin inhibitor regimen changes malignancy compared with no calcineurin inhibitor regimen (very low certainty).
1 finding from 1 review
End‐stage renal disease · adults and children who have IgA nephropathy proven on renal biopsy
It is very uncertain whether mizoribine regimen changes end‐stage kidney disease compared with no mizoribine regimen (very low certainty).
1 finding from 1 review
GFR loss ≥ 50% · adults and children who have IgA nephropathy proven on renal biopsy
Systemic corticosteroid showed no clear difference in GFR loss ≥ 50% compared with no corticosteroid regimen (low certainty).
1 finding from 1 review
Complete remission · adults and children who have IgA nephropathy proven on renal biopsy
It is very uncertain whether mizoribine regimen changes complete remission compared with no mizoribine regimen (very low certainty).
1 finding from 1 review
GFR loss ≥ 50% · adults and children who have IgA nephropathy proven on renal biopsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Annual GFR loss (mL/min/1.73 m2) · adults and children who have IgA nephropathy proven on renal biopsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found